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Reply to the Editor:
We thank Miyamoto and Miyamoto for their interest in our
recent article.1 It is a fact that ketamine is a widely known N-
methyl-D-aspartate receptor antagonist that has demonstrated
neuroprotective properties in vitro and in vivo.2 Therefore the
observed neuroprotective effect in our study is the result of
ketamine and riluzole effects. Ketamine has been widely used
by most investigators working with the rabbit model of spinal
cord ischemia, with minor spinal cord protection afforded by
this drug.2,3 In our study, all rabbits received the same dose of
ketamine, with huge differences in neurologic recovery
among experimental groups. Thus, although the potentiating
effect of ketamine cannot be ruled out, it is unlikely that this
drug by itself could account for the dramatic differences in
neurologic recovery among experimental groups. For defini-
tive assessment of the neuroprotective effects of riluzole, we
have performed a new study with a spinal cord ischemia
model in the rat.4 All animals were anesthetized with
halothane 1.5% only, and they received riluzole before aortic
crossclamping and at the onset of reperfusion. Rats were
allowed to recover for 24 (n = 15), 48 (n = 10), or 96 hours
(n = 5). In this study, riluzole again prevented neuronal necro-
sis and apoptosis and cytoskeletal proteolysis.
Regarding neurologic recovery of rabbits, we did not
observe worsening of neurologic status in riluzole-treated
rabbits between 24 and 120 hours after the operation. Rabbits
were scored at 6 hours, 24 hours, and then daily. Riluzole-
treated rabbits typically began to recover motor and sensory
function between 6 and 24 hours after the operation, whereas
control rabbits did not. Neurologic scoring before 6 hours
would have been inappropriate considering the anesthetic
properties of riluzole. In our recent study, control rats
remained severely paraplegic after the operation, whereas
riluzole-treated rats began to recover at 6 hours and had either
completely normal neurologic function or a mild to moderate
deficit up to 96 hours postoperatively.
This result is of importance because some neuroprotective
drugs can modify the early recovery but finally fail to alter
the mid-term and late recovery after spinal cord ischemia.5
Riluzole, however, not only has a transient effect, but also
may really and consistently prevent spinal cord ischemic
injury when given before aortic crossclamping.
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Measurement of chest wall forces on coughing with
the use of human cadavers
To the Editor:
We read with interest the recent article by McGregor and
associates1 on biomechanical testing of median sternotomy
closures performed on human cadavers. This work provides
the first measurement in the literature of chest wall forces on
coughing. One needs to know the magnitude of forces across
a sternotomy to test methods of sternotomy closure properly.
The norm in biomechanics is that a closure should be able to
withstand twice the potential maximum stresses. 
These first measurements of chest wall forces on coughing
are provided only indirectly. The article says that a force of
220 ± 40 N produced a lateral displacement of 1.85 ± 0.14
mm (ie, 260 N displaces 1.99 mm). Also, an intrathoracic
pressure of 63 ± 21 mm Hg displaced 2.14 ± 0.11 mm (ie, 42
mm Hg displaces 2.03 mm). Therefore, indirectly, a cough
generating 42 mm Hg produces a lateral force across a ster-
notomy of 260 N (~26 kg).
This work validates our mathematical model,2 which de-
scribes the force placed across a sternotomy closure. With our
model, where P is the distending pressure, r is the radius, l is
the height of the chest, and T is the force across the ster-
notomy,
T = rlP = 0.17m · 0.25m · 5.6 kPa = 238 N ~24 kg
the pressure of 42 mm Hg (~5.6 kPa) results in a predicted dis-
rupting force of 24 kg as compared with the measured value
of 26 kg. However, a normal cough reaches 100 mm Hg, pro-
ducing a force of 56 kg, whereas maximal coughing can gen-
erate a pressure of 300 mm Hg,3 producing a force of 168 kg.
We do not share McGregor and associates’ enthusiasm for
human cadavers. The problem in using whole human ster-
nums for biomechanical testing is in the wide biologic varia-
tion (eg, osteoporosis, metastases, age) in the samples and the
difficulty in quantifying this variation. Hence a large number
of samples is required to include bones of different quality.
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Also, multiple re-use of sternums weakens the bone, intro-
ducing further error. Therefore we use sheep sternum as our
biologic model of sternotomy closures.
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Reply to the Editor:
We appreciate the comments of Casha, Yang, and Cooper
regarding our biomechanical analysis of sternotomy closure.
It is interesting and reassuring that our measured results agree
with what is predicted by the formula that they have devel-
oped. Both studies show that physiologic amounts of force
can disrupt traditional sternal closure. We agree that a human
cadaver is not a perfect model, but neither is the sheep ster-
num. The size and shape of the ovine sternum and the
anatomic dimensions of the ovine thoracic cage are quite dif-
ferent from those of the human being. In this regard,
polyurethane foam has been used as a bone analog in ortho-
pedic research and may provide an option for additional stud-
ies in this area.
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